Skip to main content

Table 1 Clinical parameters

From: A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations

 

HC

S

E

A

SE

SA

EA

SEA

N = 105

N = 105

 

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

Age

53 ± 11

53 ± 8

56 ± 9

52 ± 10

54 ± 8

57 ± 8

56 ± 9

56 ± 8

Sex (F)

49.5%

53.3%

40.0

53.3%

46.6%

46.6%

49.5%

40.0%

BMI

28 ± 2.4

30 ± 3.2

28 ± 3.1

29 ± 2.6

28 ± 3.2

30 ± 2.7

29 ± 3.5

29 ± 2.5

PASI

8.8 ± 3.0

0.1 ± 0.3

0.2 ± 0.3

7.5 ± 2.9

9.2 ± 3.2

0.2 ± 0.3

8.0 ± 2.9

SPARCC

0 ± 0

4.2 ± 1.8

0 ± 0

2.8 ± 1.3

0 ± 0

3.5 ± 2.2

3.2 ± 1.3

SJC

0 ± 0

0 ± 0

6.1 ± 2.8

0 ± 0

5.6 ± 2.6

6.2 ± 2.6

6.4 ± 2.8

  1. HC healthy controls; monomorphic psoriatic disease manifestations: S skin disease, E enthesitis, A arthritis; polymorphic psoriatic disease manifestations: SE skin disease + enthesitis, SA skin disease + arthritis, EA enthesitis + arthritis, SEA skin + enthesitis + arthritis, BMI body mass index, PASI psoriasis area severity index, SPARCC Spondyloarthritis Research Consortium of Canada Enthesitis Index, SJC swollen joint count. All values except sex (% females) indicate means ± SEM